



## Molecular modeling and phenoloxidase inhibitory activity of arbutin and arbutin undecylenic acid ester



Ayu Masyita <sup>a, b, c</sup>, Emil Salim <sup>a, d</sup>, Rangga Meidianto Asri <sup>a, b</sup>, Firzan Nainu <sup>a, b</sup>, Aki Hori <sup>a</sup>, Risfah Yulianty <sup>b</sup>, Mochammad Hatta <sup>c</sup>, Yusnita Rifai <sup>b, \*\*</sup>, Takayuki Kuraishi <sup>a, \*</sup>

<sup>a</sup> Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan

<sup>b</sup> Faculty of Pharmacy, Hasanuddin University, Makassar, Indonesia

<sup>c</sup> Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

<sup>d</sup> Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia

### ARTICLE INFO

#### Article history:

Received 6 January 2021

Accepted 2 February 2021

Available online 17 February 2021

#### Keywords:

Arbutin

*Drosophila*

Hyperpigmentation

Melanization

Phenoloxidase

Tyrosinase inhibitor

### ABSTRACT

Excessive melanin formation has been linked to various skin disorders such as hyperpigmentation and skin cancer. Tyrosinase is the most prominent target for inhibitors of melanin production. In this study, we investigated whether arbutin and its prodrug, arbutin undecylenic acid ester, might inhibit phenoloxidase (PO), a tyrosinase-like enzyme. Molecular docking simulation results suggested that arbutin and arbutin undecylenic acid ester can bind to the substrate-binding pocket of PO. Arbutin undecylenic acid ester with an  $IC_{50}$  6.34 mM was effective to inhibit PO compared to arbutin ( $IC_{50}$  29.42 mM). In addition, arbutin undecylenic acid ester showed low cytotoxicity in *Drosophila* S2 cells and the compound inhibited the melanization reaction. Therefore, the results of this study have demonstrated that arbutin undecylenic acid ester as a potential inhibitor of PO. We successfully designed a new platform utilizing *Drosophila melanogaster* and *Bombyx mori* as animal models propounding fast, cheap, and high effectiveness in method to screen tyrosinase inhibitors.

© 2021 Elsevier Inc. All rights reserved.

### 1. Introduction

Melanin is a pigment that plays an important role in human skin pigmentation which is produced by melanocytes through melanogenesis [1]. Skin pigmentation is a photoprotective factor mainly responsible for photo-carcinogenesis of the skin and harmful ultraviolet radiation [2,3]. However, excessive production of melanin can be a dermatologically serious problem leading to skin cancer and facial aesthetics in humans [4–6]. Apart from cosmetic considerations, treatment of skin pigmentation may also improve the quality of life.

In recent years, many substances have become available to treat hyperpigmentation disorder through various mechanisms [7] and tyrosinase, the key enzyme of the biosynthetic melanin pathway, has been the obvious molecular target for inhibiting this abnormality [8,9]. This enzyme belongs to the type 3 copper-containing

metalloprotein with binuclear copper ions, CuA and CuB, coordinated by histidine residues as the conserved active site [10].

Many compounds have been identified as tyrosinase inhibitors, but only a few are currently used in topical dermatological products due to lack of clinical efficacy [11,12]. Hydroquinone is one of potent inhibitors against tyrosinase since the early 1990s [13]. However, the use of hydroquinone has been banned since January 2001 due to medium-term effects such as white patches on the skin, exogenous ochronosis, and carcinogenic for long-term effect [14]. Therefore, an increasing interest in discovery and development of tyrosinase inhibitors are observed especially in the cosmetics industry, and arbutin is the most well-studied among them [15–17].

Instead of human tyrosinase, mushroom tyrosinase isolated from *Agaricus bisporus* is more frequently used as an in vitro model for screening tyrosinase inhibitors, since this enzyme is commercially available [18]. However, previous studies have reported significant differences in inhibitor effectiveness between mushroom tyrosinase (mTyr) and human tyrosinase (hTyr) [19,20]. Moreover, structural and kinetic information of human tyrosinase still remains unclear [21].

\* Corresponding authors.

\*\* Corresponding author.

E-mail addresses: [yusnita@fmipa.unhas.ac.id](mailto:yusnita@fmipa.unhas.ac.id) (Y. Rifai), [tkuraishi@staff.kanazawa-u.ac.jp](mailto:tkuraishi@staff.kanazawa-u.ac.jp) (T. Kuraishi).

In line with our study, the results lead us to establish a new approach for an efficient and effective *in vitro* and *in vivo* screening of tyrosinase inhibitors by utilizing PO from fruit flies, *Drosophila melanogaster* and silkworms, *Bombyx mori*. PO has similar activity with tyrosinase in mammals that catalyzes the *o*-hydroxylation of monophenols to *o*-diphenols and the oxidation of *o*-diphenols to quinones [22,23]. This new platform is simple preparation, easy, and low cost. We identified the effects of popular skin whitening agents that inhibit tyrosinase as well as PO, such as tropolone and kojic acid [24,25] and compared their efficacy with arbutin and its derivative, arbutin undecylenic acid ester. We found that arbutin undecylenic acid ester is effective and safe as a PO inhibitor.

## 2. Materials and methods

### 2.1. Compounds and reagents

Arbutin undecylenic acid ester was enzymatically synthesized by esterification reaction as described previously [26]. Arbutin and kojic acid were obtained from TCI Technology Co., Ltd., (Tokyo, JP). Tropolone and L-DOPA were obtained from Wako Pure Chemical Industries, Ltd., (Osaka, JP). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless otherwise noted.

### 2.2. Cell culture

*Drosophila* S2 cell lines were maintained at 25 °C in Schneider's *Drosophila* medium (Thermo Fisher SCIENTIFIC) containing 10% (v/v) heat-inactivated FBS, 100 units/mL penicillin, and 100 mg/mL streptomycin.

### 2.3. Animal stocks and maintenance

*Drosophila* stocks were maintained in standard cornmeal-yeast agar medium at 25 °C or 18 °C. Oregon R flies were used as a wild-type. *Bombyx mori* stocks were maintained in mulberry chow silkworm food at 25 °C.

### 2.4. Molecular docking

The molecular structure of PO and tyrosinase was obtained from Protein Data Bank (PDB ID: 3HHS and 2Y9W, respectively). Preparation of proteins and rotatable bonds in the ligands were assigned by AutoDockTools4 program. Docking was performed by directing the optimized ligand molecular model on the active site of the enzymes using AutoDock Vina [27] for three replications. The protein-ligand interactions were visualized and analyzed using PyMOL. The amino acid sequences were retrieved from the UniProt database (<http://www.uniprot.org/>).

### 2.5. PO inhibitory activity assay

Silkworm hemolymph was collected by dissecting the legs of the 5th instar larvae of *B. mori*. 5 µL of compounds were added into a 96-well plate. Then, hemolymph solution was prepared by combining 50 µL of diluted hemolymph (5 µL of hemolymph in 45 µL of protease inhibitor cocktail) with 150 µL of a 5 mM CaCl<sub>2</sub> solution in a clean Eppendorf tube. Next, add 800 µL of L-DOPA solution (20 mM in phosphate buffer pH 6.6). Following thorough mixing, 45 µL of hemolymph solution was added into each well to a final volume 50 µL and incubated at 29 °C in the dark for 30 min. After that, the optical density (OD) at 492 nm was measured for each sample against negative control containing no compound. Each experiment was repeated three times. The intensity of the color observed will depend on the initial amount of cleaved PO in

the sample. The data from this assay reflect the PO activity at the time of collection due to activation of the prophenoloxidase (PPO) was blocked by the presence of the protease inhibitor [28].

### 2.6. Cell viability assay

*Drosophila* S2 cells ( $1.5\text{--}8.0 \times 10^5$  cells in 100 µL) were inoculated in a 96-well plate. 10 µL of compounds, arbutin, arbutin ester, tropolone, and kojic acid were added and incubated at 25 °C for 12–18 h. Cell viability was monitored by luminescence from a CellTiter-Glo Luminescent Cell Viability Assay (Promega) with a Synergy-HTX (BioTek). Cell viability is expressed as a relative value, with luminescence in cells incubated with the Elix water (negative control) being 100%.

### 2.7. Melanization assessment

To observe PO inhibitory activity during melanization, we performed pinching of 3rd instar larvae (unless otherwise noted) and pricking the adult flies of wild-type, Oregon R, after feeding with compounds for five days. For imaging of the melanization reaction upon pricking, the thorax of the animal was pricked using a sterilized needle. Pictures were taken 16 h post-pricking. Third-instar larvae were pinched dorsally near the posterior end. Pictures of melanized larvae were taken 3 h post-injury [29]. Pictures were captured with an Olympus SZX16 microscope, an Olympus DP74 camera and the Olympus Application Suite. For publication purposes, contrast and brightness were increased on some images.

### 2.8. Statistical analysis

Statistical significance of PO inhibitory activity and cytotoxicity data was calculated with 2-way ANOVA with Tukey's multiple comparisons test. Statistical significance of survival data was calculated with a log-rank test compared to the water group. Blackening strength (strong, weak, or none) of the larvae and adult flies were analyzed using Chi-square test. P values are indicated in figure legends.


## 3. Results

### 3.1. Molecular modeling

In insects, PO refers to an enzyme with tyrosinase-like activity. The main role of PO as a key component in melanogenesis is to convert phenols to quinones, which subsequently polymerize to form melanin (Fig. 1A and B). The *Drosophila* genome encodes three isoforms of PPO, two of them, PPO1 and PPO2 contribute to melanization [30]. We checked the amino acid sequences of PPO1 and PPO2 of *D. melanogaster* and *B. mori*. The result showed homology when its amino acid sequences were aligned with that of human tyrosinase and mushroom tyrosinase isoforms (PPO3 and PPO4, the main components of commercially available mTyr) (Fig. 1C).

To evaluate the interaction of compounds with PO and tyrosinase, we performed molecular docking. With the docking strategies, the orientation of the ligand when it is bound to an enzyme or protein can be predicted [31]. In PO, arbutin has low binding energy compared to other compounds (Table 1). On the other hand, arbutin ester has similar binding energy with tropolone and kojic acid as positive controls (Fig. 2). The results suggest that arbutin ester could bind closer to the active site of PO. The same interaction was also shown in the arbutin ester against the tyrosinase.





**Fig. 2.** Docking poses of phenoloxidase inhibitors. (A) The binding mode of phenoloxidase (blue sticks) with arbutin (red sticks), (B) arbutin ester (green sticks), (C) tropolone (blue sticks), and kojic acid (magenta sticks). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

none). Interestingly, as we expected, blackening reaction of arbutin ester group (15% strong, 47% weak, 38% none) was not significantly different with kojic acid as positive control group (13% strong, 42% weak, 45% none), whereas tropolone group were almost deficient for blackening (3% strong, 15% weak, 82% none) (Fig. 4B).


Concordant with blackening reaction in larvae, after pricking, the water group 56% blacken strongly and 44% blacken weakly. Blackening reactions of arbutin and arbutin ester group were 11% strong, 44% weak, 39% none and 17% strong, 66% weak, 17% none, respectively (Fig. 4C).

We also reveal that the melanization responses were contributed with survival in adult flies post-injury. A synergistic effect can be observed in arbutin ester group, we noticed that they have a significantly lower survival rate than the arbutin, tropolone, and water group (Fig. 4D). A similar trend towards reduced survival rate was evaluated in kojic acid group. However, as shown in Supplemental Fig. 1, we examined the effects of the compounds on survival rates without pricking and we confirmed that the kojic acid being strongly lower survival rates than other compounds. This indicates that arbutin ester was potent and safe as an inhibitor of PO with a remarkable efficacy not only in vitro but also in vivo over other compounds.


#### 4. Discussion

Tyrosinase inhibitors are highly warranted by pharmaceutical and cosmetic industries for skin whitening agents. Most tyrosinase inhibitors have been evaluated with mushroom tyrosinase. However, recent research has reported that the commercially available mushroom tyrosinase is a mixture of several tyrosinase isoenzymes and additional enzyme activity that may influence inhibition studies [32]. Thus, it is important to explore an alternative model for screening the tyrosinase inhibitor. The main objective of this study was to investigate the effects of derivative of arbutin, arbutin undecylenic acid ester using PO from *D. melanogaster* and *B. mori* as a new model.

Although arbutin had already been identified as a tyrosinase inhibitor, the published  $IC_{50}$  values of arbutin range from 0.04 mM to more 30 mM for mTyr [33]. Mann [34] reported that arbutin only weakly inhibited human tyrosinase. On the other hand, penetration of arbutin through the skin to reach the melanocytes is rather difficult due to low hydrophobicity ( $\log P$  value =  $-1.49$ ) [35]. Therefore, new derivatives of arbutin are being sought out.



**Fig. 3.** Inhibition of phenoloxidase and the cytotoxicity effect of compounds. (A) % Inhibitory and (B)  $IC_{50}$  of arbutin, arbutin ester, tropolone, and kojic acid ( $***P = 0.0001$ ;  $****P < 0.0001$ ;  $ns P > 0.05$ ). (C) % Lethality and (D)  $LC_{50}$  of arbutin, arbutin ester, tropolone, and kojic acid ( $P = 0.0326$ ;  $**P = 0.0021$ ;  $***P = 0.0002$ ). Data represent the mean  $\pm$  SEM of experiments performed in triplicate (A–D).



**Fig. 4.** Melanization reaction in *D. melanogaster*. (A) Category of blackening reaction: strong, weak, and none. (B) Blackening reaction of larvae (arbutin vs arbutin ester  $P = 0.0002$ , tropolone vs arbutin ester  $P < 0.0001$ , kojic acid vs arbutin ester  $P = 0.6023$ , and water vs arbutin ester  $P < 0.0001$ ). (C) Blackening reaction of adult flies of *Drosophila melanogaster* after treatment with compounds (arbutin vs arbutin ester  $P = 0.0008$ , tropolone vs arbutin ester  $P = 0.0060$ , kojic acid vs arbutin ester  $P = 0.0031$ , and water vs arbutin ester  $P < 0.0001$ ). (D) Survival rate of flies post-injury (water vs arbutin  $P = 0.5176$ , water vs arbutin ester  $P = 0.0010$ , water vs tropolone  $P = 0.2790$ , water vs kojic acid  $P = 0.0007$ ).

Arbutin undecylenic acid ester is an arbutin prodrug from enzymatic esterification of arbutin and undecylenic acid which is considered to maintain the stability of the physical and chemical properties of arbutin and as a strategy for enhancing the absorption in human skin because of the acylation with chain fatty acid may increase the hydrophobicity (prediction of log P value = 3.37). Ester prodrugs have been targets of a number of studies in recent decades, especially for applications in cosmetic products [36].

Our docking data reveal that the arbutin undecylenic acid ester can bind to the substrate-binding pocket of PO (Fig. 2). The hydroxyl group of the compound has been proposed as essential structural requirements to display inhibitory activities against PO due to their chelating properties [37]. The results are in agreement with previous studies which in tropolone, kojic acid, and arbutin, take part in chelation in inhibiting tyrosinase [38].

Tropolone and kojic acid have been known as strong inhibitors of tyrosinase [39]. Nevertheless, tropolone was never seriously considered for clinical developments in humans due to its highly toxic substances [40]. Our results exhibit tropolone has  $IC_{50}$  values about 0.38 mM and significantly cytotoxic in *Drosophila* S2 cells (Fig. 3). Additionally, our study found that the growth of larvae has delayed after feeding with the tropolone and kojic acid. Regarding the safety of kojic acid for cosmetic products, the European Scientific Committee on Consumer Safety [41] considers kojic acid at concentrations up to 1.0% to be safe. However, due to cytotoxic and instability on storage, its use has been limited [42].

In our *in vitro* experiments, we used hemolymph (insect blood) from the silkworm, *B. mori*. PO exists in hemolymph, which is primarily produced as the inactive zymogen, PPO [43]. We found that arbutin ester with an  $IC_{50}$  6.34 mM was effective to inhibit PO compared to arbutin (Fig. 3A and B). Further experiments exhibited that arbutin and arbutin ester was low cytotoxic activity (Fig. 3C and D). However, the European Union Scientific Committee on Consumer Products [44] published a critical opinion regarding the use of arbutin to be unsafe in cosmetics products because it can release hydroquinone from the molecule.

In melanization assessment, we performed injury in the larvae and adult flies of *D. melanogaster*. Upon injury, they release PPOs into the hemolymph, where they are activated by a cascade of patterns-recognition proteins, serine proteases (SPs) [29]. These

experiments confirmed that arbutin ester can inhibit the melanization reaction (Fig. 4). Binggeli [45] have analyzed the association of melanization to survival of flies. They showed that  $PPO1^4$ ,  $PPO2^4$  double mutants have a significantly shorter lifespan than the wild-type flies. Therefore, our results suggested that the arbutin undecylenic acid ester might provide important information for the development of pigmentation-related skin diseases and serve as a useful skin whitening agent in future cosmeceutical applications.

Furthermore, the results of this study have demonstrated that *D. melanogaster* and *B. mori* provide new insight and alternatives into novel melanogenesis inhibitor discovery. There are many advantages of using these animal models, they are inexpensive and easy to culture in laboratory conditions [46]. This new platform is simple, economic, and high-throughput screening for the rapid determination of tyrosinase inhibitors. Better yet, the low-cost of this platform enables researchers to conduct large-scale drug screening at keen prices. In comparison, commercial tyrosinase inhibitor screening kit demand an exorbitant price and only available for *in vitro* assay. In fact, the most striking feature of this new platform is that it can enable researchers to screen potential tyrosinase inhibitors efficiently not only *in vitro* but also *in vivo* assays, as well as it can be detected the toxicity effect of compounds.

## 5. Conclusions

Arbutin undecylenic acid ester was potent and safe as PO inhibitor as well as tyrosinase inhibitor. Indeed, *D. melanogaster* and *B. mori* could be used as a new efficient and effective platform for screening tyrosinase inhibitors. The full potential of arbutin undecylenic acid ester to reduce hyperpigmentation of human skin and the powerful *D. melanogaster* and *B. mori* as an alternative model need to be explored in future studies.

## Funding

This work was supported by a grant of Japan Student Services Organization (JASSO scholarship) and a grant of the Ministry of Research, Technology and Higher Education of the Republic of Indonesia (grant number 1517/UN4.22/PT.01.03/2020).

## Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Acknowledgments

We are grateful to Kanazawa University Short-term Exchange Program for Science and Technology (KUEST), Kanazawa University, Japan. We acknowledge the technical support for melanization assessment from Mr. Chin Shi.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bbrc.2021.02.006>.

## References

- S.A.N. D'Mello, G.J. Finlay, B.C. Baguley, M.E. Askarian-Amiri, Signaling pathways in melanogenesis, *Int. J. Mol. Sci.* 17 (2016) 1144, <https://doi.org/10.3390/ijms17071144>.
- S. Saxena, R.M. Andersen, H.I. Maibach, Pitfalls in clinical trials reveal need for well tolerated, more effective depigmenting agents, *J. Dermatol. Treat.* 26 (2015) 440–450, <https://doi.org/10.3109/09546634.2014.998609>.
- T. Pillaiyar, M. Manickam, V. Namasivayam, Skin whitening agents: medicinal chemistry perspective of tyrosinase inhibitors, *J. Med. Chem.* 61 (2018) 7395–7418, <https://doi.org/10.1080/14756366.2016.1256882>.
- L.L. Baxter, W.J. Pavan, The etiology and molecular genetics of human pigmentation disorders, Wiley, *Interdiscip. Rev. Dev. Biol.* 2 (2013) 379–392, <https://doi.org/10.1002/wdev.72>.
- S. del Bino, C. Duval, F. Bernerd, Molecular sciences clinical and biological characterization of skin pigmentation diversity and its consequences on UV impact, *Int. J. Mol. Sci.* 19 (2018) 2668, <https://doi.org/10.3390/ijms19092668>.
- B.H. Kim, K. Chan Park, J. Ho Park, C.G. Lee, S.K. Ye, J.Y. Park, Inhibition of tyrosinase activity and melanin production by the chalcone derivative 1-(2-cyclohexyl methyl-6-hydroxy-phenyl)-3-(4-hydroxymethyl-phenyl)-propanone, *Biochem. Biophys. Res. Commun.* 480 (2016) 648–654, <https://doi.org/10.1016/j.bbrc.2016.10.110>.
- S. Briganti, E. Camera, M. Picardo, Chemical and instrumental approaches to treat hyperpigmentation, *Pigm. Cell Res.* 16 (2003) 101–110, <https://doi.org/10.1034/j.1600-0749.2003.00029.x>.
- S.Y. Lee, N. Baek, T.G. Nam, Natural, semisynthetic and synthetic tyrosinase inhibitors, *J. Enzym. Inhib. Med. Chem.* 31 (2015) 1–13, <https://doi.org/10.3109/14756366.2015.1004058>.
- T. Oyama, S. Takahashi, A. Yoshimori, T. Yamamoto, A. Sato, T. Kamiya, H. Abe, T. Abe, S.-I. Tanuma, Discovery of a new type of scaffold for the creation of novel tyrosinase inhibitors, *Bioorg. Med. Chem.* 24 (2016) 4509–4515, <https://doi.org/10.1016/j.bmc.2016.07.060>.
- C.A. Ramsden, P.A. Riley, Tyrosinase: the four oxidation states of the active site and their relevance to enzymatic activation, oxidation and inactivation, *Bioorg. Med. Chem.* 22 (2014) 2388–2395, <https://doi.org/10.1016/j.bmc.2014.02.048>.
- T.S. Chang, An updated review of tyrosinase inhibitors, *Int. J. Mol. Sci.* 10 (2009) 2440–2475, <https://doi.org/10.3390/ijms10062440>.
- S. Zolghadri, A. Bahrami, M. Tareq, H. Khan, J. Munoz-Munoz, F. Garcia-Molina, F. Garcia-Canovas, A.A. Saboury, A comprehensive review on tyrosinase inhibitors, *J. Enzym. Inhib. Med. Chem.* 34 (2019) 279–309, <https://doi.org/10.1080/14756366.2018.1545767>.
- A. Palumbo, M. d'Ischia, G. Misuraca, G. Prota, Mechanism of inhibition of melanogenesis by hydroquinone, *Biochim. Biophys. Acta* 1073 (1991) 85–90, [https://doi.org/10.1016/0304-4165\(91\)90186-K](https://doi.org/10.1016/0304-4165(91)90186-K).
- T.J. Kooyers, W. Westerhof, Toxicological aspects and health risks associated with hydroquinone in skin bleaching formula, *Ned. Tijdschr. Geneesk.* 148 (2004) 768–771.
- A. Garcia-Jimenez, J. Antonio Teruel-Puche, J. Berna, J. Neptuno Rodriguez-Lopez, J. Tudela, F. Garcia-Canovas, Action of tyrosinase on alpha and beta-arbutin: a kinetic study, *PLoS One* 12 (2017), e017733, <https://doi.org/10.1371/journal.pone.0177330>.
- A. Masyita, Y. Rifai, Molecular docking studies of arbutin derivatives as tyrosinase inhibitors, *Int. J. Biosci. Biochem. Bioinform.* 9 (2019) 188–193, <https://doi.org/10.17706/ijbbb.2019.9.3.188-193>.
- H. Zhou, J. Zhao, A. Li, M.T. Reetz, Chemical and biocatalytic routes to arbutin, *Molecules* 24 (2019) 3303, <https://doi.org/10.3390/molecules24183303>.
- W.T. Ismaya, H.J. Rozeboom, A. Weijn, J.J. Mes, F. Fusetti, H.J. Wichers, B.W. Dijkstra, Crystal structure of agaricus bisporus mushroom tyrosinase: identity of the tetramer subunits and interaction with tropolone, *Biochemistry* 50 (2011) 5477–5486, <https://doi.org/10.1021/bi200395t>.
- Y.M. Ha, Y.J. Park, J.Y. Lee, D. Park, J. Choi, E.K. Lee, J.M. Kim, J.-A. Kim, J.Y. Park, H.J. Lee, H. Ryong Moon, H.Y. Chung, Design, synthesis and biological evaluation of 2-(substituted phenyl) thiazolidine-4-carboxylic acid derivatives as novel tyrosinase inhibitors, *Biochimie* 94 (2011) 533–540, <https://doi.org/10.1016/j.biochi.2011.09.002>.
- A. Vontzalidou, G. Zoidis, E. Chaita, M. Makropoulou, N. Aligiannis, G. Lambrinidis, E. Mikros, A.L. Skaltsounis, Design, synthesis and molecular simulation studies of dihydrostilbene derivatives as potent tyrosinase inhibitors, *Bioorg. Med. Chem. Lett.* 22 (2012) 5523–5526, <https://doi.org/10.1016/j.bmcl.2012.07.029>.
- P. Cordes, W. Sun, R. Wolber, L. Kolbe, G. Klebe, K.H. Röhm, Expression in non-melanogenic systems and purification of soluble variants of human tyrosinase, *Biol. Chem.* 394 (2013) 685–693, <https://doi.org/10.1515/hsz-2012-0300>.
- J.P. Dudzic, S. Kondo, R. Ueda, C.M. Bergman, B. Lemaitre, *Drosophila* innate immunity: regional and functional specialization of prophenoloxidases, *BMC Biol.* 13 (2015) 81, <https://doi.org/10.1186/s12915-015-0193-6>.
- I. Eleftherianos, C. Revenis, Role and importance of phenoloxidase in insect hemostasis, *J. Innate. Imm.* 3 (2011) 28–33, <https://doi.org/10.1159/000321931>.
- B. Deri, M. Kanteev, M. Goldfeder, D. Lecina, V. Guallar, N. Adir, A. Fishman, The unravelling of the complex pattern of tyrosinase inhibition, *Sci. Rep.* 6 (2016) 34993, <https://doi.org/10.1038/srep34993>.
- D. Nokinsee, L. Shank, V.S. Lee, P. Nimmanpipug, Estimation of inhibitory effect against tyrosinase activity through homology modeling and molecular docking, *Enzym. Res.* (2015) 262364, <https://doi.org/10.1155/2015/262364>.
- Y. Tokiwa, M. Kitagawa, T. Raku, S. Yanagitani, K. Yoshino, Enzymatic synthesis of arbutin undecylenic acid ester and its inhibitory effect on melanin synthesis, *Bioorg. Med. Chem. Lett.* 17 (2007) 3105–3108, <https://doi.org/10.1016/j.bmcl.2007.03.039>.
- O. Trott, A.J. Olson, AutoDock Vina, Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multi-threading, *J. Comput. Chem.* 31 (2010) 455–461, <https://doi.org/10.1002/jcc.21334>.
- K. Troha, N. Buchon, Methods for the study of innate immunity in *Drosophila melanogaster*, *WIREs. Dev. Biol.* 8 (2019) e344, <https://doi.org/10.1002/wdev.344>.
- J.P. Dudzic, M.A. Hanson, I. Iatsenko, S. Kondo, B. Lemaitre, More than black or white: melanization and toll share regulatory serine proteases in *Drosophila*, *Cell Rep.* 27 (2019) 1050–1061, <https://doi.org/10.1016/j.celrep.2019.03.101>.
- A. Lu, Q. Zhang, J. Zhang, B. Yang, K. Wu, W. Xie, Y.X. Luan, E. Ling, R. Chandrasekar, Insect prophenoloxidase: the view beyond immunity, *Front. Physiol.* 5 (2014), e00252, <https://doi.org/10.3389/fphys.2014.00252>.
- V. Salmaso, S. Moro, Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: an overview, *Front. Pharmacol.* 9 (2018) 923, <https://doi.org/10.3389/fphar.2018.00923>.
- M. Pretzler, A. Bijelic, A. Rempel, Heterologous expression and characterization of functional mushroom tyrosinase (AbPPO4), *Sci. Rep.* 7 (2017) 1810, <https://doi.org/10.1038/s41598-017-01813-1>.
- K. Sugimoto, K. Nomura, T. Nishimura, T. Kiso, K. Sugimoto, T. Kuriki, Syntheses of  $\alpha$ -arbutin- $\alpha$ -glycosides and their inhibitory effects on human tyrosinase, *J. Biosci. Bioeng.* 99 (2005) 272–276, <https://doi.org/10.1263/jbb.99.272>.
- T. Mann, W. Gerwat, J. Batzer, K. Eggers, C. Scherner, H. Wenck, F. Stäb, V.J. Hearing, K.-H. Röhm, L. Kolbe, Inhibition of human tyrosinase requires molecular motifs distinctively different from mushroom tyrosinase, *J. Invest. Dermatol.* 138 (2018) 1601–1608, <https://doi.org/10.1016/j.jid.2018.01.019>.
- N.S. Ayumi, S. Sahudin, Z. Hussain, M. Hussain, N.H. A Samah, Polymeric nanoparticles for topical delivery of alpha and beta arbutin: preparation and characterization, *Drug Deliv. and Transl. Res.* 9 (2019) 482–496, <https://doi.org/10.1007/s13346-018-0508-6>.
- I. Antonopoulou, S. Varriale, E. Topakas, U. Rova, P. Christakopoulos, V. Faraco, Enzymatic synthesis of bioactive compounds with high potential for cosmetic application, *Appl. Microbiol. Biotechnol.* 100 (2016) 6519–6543, <https://doi.org/10.1007/s00253-016-7647-9>.
- E. Muñoz, J.G. Avila, J. Alarcón, I. Kubo, E. Werner, C.L. Céspedes, Tyrosinase inhibitors from *Calceolaria integrifolia* s.l.: *Calceolaria talcana* aerial parts, *J. Agric. Food Chem.* 61 (2013) 4336–4343, <https://doi.org/10.1021/jf400531h>.
- L. Panzella, A. Napolitano, Natural and bioinspired phenolic compounds as tyrosinase inhibitors for the treatment of skin hyperpigmentation: recent advances, *Cosmetics* 6 (2019) 57, <https://doi.org/10.3390/cosmetics6040057>.
- A. Rescigno, F. Sollai, B. Pisu, A. Rinaldi, E. Sanjust, Tyrosinase inhibition: general and applied aspects, *J. Enzym. Inhib. Med. Chem.* 17 (2002) 207–218, <https://doi.org/10.1080/1475636021000010923>.
- D.A. Learmonth, L.E. Kiss, P. Soares-da-Silva, The chemistry of catechol-*o*-methyltransferase inhibitors, *Int. Rev. Neurobiol.* 95 (2010) 119–162, <https://doi.org/10.1016/B978-0-12-381326-8.00006-5>.
- Scientific Committee on Consumer Safety, Opinion on Kojic Acid, 2012, [https://ec.europa.eu/health/scientific\\_committees/consumer\\_safety/docs/sccs\\_o\\_098.pdf](https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_098.pdf). (Accessed 18 December 2020).
- E.K. Kim, B.K. Singh, S.H. Park, H.B. Lee, Y.A. Goo, H.S. Kim, S.H. Cho, J.H. Lee, G.W. Ahn, J.P. Kim, S.M. Kang, E.K. Kim, Peptide as a tyrosinase inhibitor kojic acid peptide: a new compound with anti-tyrosinase potential, *Ann. Dermatol.* 28 (2016) 1013–9087, <https://doi.org/10.5021/ad.2016.28.5.555>.
- K.D. Clark, M.R. Strand, Hemolymph melanization in the silkworm *Bombyx*

- mori* involves formation of a high molecular mass complex that metabolizes tyrosine, *J. Biol. Chem.* 288 (2013) 14476–14487, <https://doi.org/10.1074/jbc.M113.459222>.
- [44] Scientific Committee on Consumer Products, Opinion on  $\beta$ -arbutin, 2015. [https://ec.europa.eu/health/scientific\\_committees/consumer\\_safety/docs/sccs\\_o\\_169.pdf](https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_169.pdf). (Accessed 17 September 2020).
- [45] O. Binggeli, C. Neyen, M. Poidevin, B. Lemaitre, Prophenoxidase activation is required for survival to microbial infections in *Drosophila*, *PLoS Pathog.* 10 (2014), e1004067, <https://doi.org/10.1371/journal.ppat.1004067>.
- [46] B. H Jennings, *Drosophila* - a versatile model in biology & medicine, *Mater. Today* 14 (2011) 190–195, [https://doi.org/10.1016/S1369-7021\(11\)70113-4](https://doi.org/10.1016/S1369-7021(11)70113-4).